Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Key facts

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Principal Investigator

Jean William Pape, MD, M.D

Cornell - GHESKIO, Institut de Laboratoire et de Recherches and Division of International Medicine and Infectious Diseases, Cornell University

Intervention

Efavirenz(drug)

Enrollment

816 enrolled

Eligibility

18 years · All sexes

Timeline

2007 – 2009

Study locations (1)

• Les Centres GHESKIO CIPRA CRS, Port-au-Prince, Haiti

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05917210
  Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
  Yale University
• RECRUITINGNCT07312266
  Questioning the Epidemiology of Asymptomatic TB
  Barcelona Institute for Global Health
• RECRUITINGNANCT05842161
  South Africa Smoking Cessation and Engagement in HIV/TB Care Care
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT05575518
  A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
  Stellah Mpagama
• ACTIVE NOT RECRUITINGPHASE4NCT05118490
  Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
  The Aurum Institute NPC
• RECRUITINGNANCT05342064
  Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
  Baylor College of Medicine

See all trials for Primary genito-urinary tuberculosis →